Back to Agenda
Session 8: Suitability of Current Regulatory and HTA Frameworks for New High Value Curative Technologies
Session Chair(s)
Lucia D'Apote, DrSc, RAC
Executive Director Global Regulatory and R&D Policy (ELMAC and JAPAC)
Amgen, Switzerland
A panel of experts will discuss: A panel of experts will discuss: 1.How Regulators and HTA can collaborate more closely to define mutual evidence requirements for better patient access? 2.Are the current regulatory and HTA frameworks suitable for the new curative technologies – where are the gaps? 3.How health systems define value proposition for new curative technologies?
Speaker(s)
Panel Discussion
Flora Giorgio, MPharm
European Commission, Belgium
Deputy Head of Unit Medical Devices, DG SANTE – Medical Products and Innovation
Panel Discussion
Michael Berntgen, PhD
European Medicines Agency, Netherlands
Head of Scientific Evidence Generation
Panel Discussion
François Houyez
European Organisation for Rare Diseases (EURORDIS), France
Treatment Information and Access Director, Health Policy Advisor
Panel Discussion
Ansgar Hebborn, PhD, MBA
F. Hoffmann-La Roche AG, Switzerland
Head - Access Policy Affairs Europe
Have an account?